Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390:681–96. https://doi.org/10.1016/s0140-6736(17)30062-4.

Article  PubMed  Google Scholar 

Michael M, Bagga A, Sartain SE, Smith RJH. Haemolytic uraemic syndrome. Lancet. 2022;400:1722–40. https://doi.org/10.1016/s0140-6736(22)01202-8.

Article  PubMed  CAS  Google Scholar 

Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11:2–15.

PubMed  Google Scholar 

McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the correct diagnosis in thrombotic microangiopathy: a narrative review. Can J Kidney Health Dis. 2021;8:20543581211008708. https://doi.org/10.1177/20543581211008707.

Article  PubMed  PubMed Central  Google Scholar 

Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23:4–21. https://doi.org/10.1111/1744-9987.12763.

Article  PubMed  Google Scholar 

Mannucci PM, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: laboratory weapons and their impact on treatment choice and monitoring. Thromb Res. 2015;136:851–4. https://doi.org/10.1016/j.thromres.2015.09.007.

Article  PubMed  CAS  Google Scholar 

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91:539–51. https://doi.org/10.1016/j.kint.2016.10.005.

Article  PubMed  CAS  Google Scholar 

Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125:3253–62. https://doi.org/10.1182/blood-2014-09-600411.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81. https://doi.org/10.1056/NEJMoa1208981.

Article  PubMed  CAS  Google Scholar 

Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701–11. https://doi.org/10.1016/j.kint.2015.11.026.

Article  PubMed  CAS  Google Scholar 

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061–73. https://doi.org/10.1038/ki.2014.423.

Ito S, Hataya H, Ashida A, Hamada R, Ishikawa T, Ishikawa Y, Shimono A, Konomoto T, Miyazawa T, Ogura M, Tanaka K, Kagami S. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrol Dial Transplant. 2023;38:414–24. https://doi.org/10.1093/ndt/gfac150.

Article  PubMed  CAS  Google Scholar 

Maruyama S, Ikeda Y, Kaname S, Kato N, Matsumoto M, Ishikawa Y, Shimono A, Miyakawa Y, Nangaku M, Shibagaki Y, Okada H. Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance. J Nephrol. 2024; in press. https://doi.org/10.1007/s40620-024-01921-y.

Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, Fukamizu Y, Akiyama H, Hayashi H, Nakano T, Maruyama S. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2023;118:419–31. https://doi.org/10.1007/s12185-023-03630-x.

Article  PubMed  CAS  Google Scholar 

Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185:297–310. https://doi.org/10.1111/bjh.15790.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020;97:1287–96. https://doi.org/10.1016/j.kint.2020.01.035. Erratum: Kidney Int. 2020;98:1621. https://doi.org/10.1016/j.kint.2020.11.001. Corrigendum: Kidney Int. 2021;99:1244. https://doi.org/10.1016/j.kint.2021.03.008.

Ultomiris package insert. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/870056_6399427A2023_1_01.

Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021;100:225–37. https://doi.org/10.1016/j.kint.2020.10.046. Corrigendum: Kidney Int. 2023;104:205. https://doi.org/10.1016/j.kint.2023.04.010.

Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021;6:1603–13. https://doi.org/10.1016/j.ekir.2021.03.884.

Article  PubMed  PubMed Central  Google Scholar 

Dixon PB, Kavanagh D, Aris MDA, Adams B, Kang GH, Wang E, Garlo K, Ogawa M, Chakravarty SAP, Heyne N, Kim HS, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum AL. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med. 2024; in press. https://doi.org/10.1016/j.xkme.2024.100855.

Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30:127–34. https://doi.org/10.1007/s40620-016-0288-3.

Article  PubMed  Google Scholar 

Dorgalaleh A, Mahmudi M, Tabibian S, Khatib ZK, Tamaddon GH, Moghaddam ES, Bamedi T, Alizadeh S, Moradi E. Anemia and thrombocytopenia in acute and chronic renal failure. Int J Hematol Oncol Stem Cell Res. 2013;7:34–9.

PubMed  PubMed Central  Google Scholar 

Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int. 2012;82:147–57. https://doi.org/10.1038/ki.2012.130.

Article  PubMed  CAS  Google Scholar